Puerarin and cardiovascular outcomes: a systematic review of clinical evidence and safety
Zhou YX, Zhang H, Peng C
Published in Phytotherapy Research
Methodology
Systematic review of pharmacology and clinical reports on puerarin, the principal kudzu isoflavone, including cardiovascular applications and adverse events
Key Findings
Clinical evidence for puerarin in cardiovascular disease is limited to small, poorly controlled trials, and intravenous puerarin has been linked to haemolysis reports.
Conclusions
Kudzu's cardiovascular claims rest on weak clinical evidence with real safety caveats for injectable forms.
Limitations
Predominantly Chinese-language low-quality trials; publication bias likely.
Supplements Studied
Clinical evidence for puerarin in cardiovascular disease is limited to small, poorly controlled trials, and intravenous puerarin has been linked to haemolysis reports.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.